A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs HTI immunogen (Primary) ; Vesatolimod (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Acronyms AELIX-003
- Sponsors Aelix Therapeutics
- 05 Jul 2019 Status changed from planning to suspended.
- 26 Oct 2018 New trial record
- 18 Oct 2018 According to an Aelix Therapeutics media release, the initiation of AELIX-003 is targeted for early 2019.